Empirical test of Fama French three factor model and illiquidity premium in Indonesia

Tests Of The Fama And French Three Factor Model In Iran

test of the fama-french three-factor model in tehran stock exchange

0

tests of the fama and french three factor model in iran

Intertemporal Capital Asset Pricing and the Fama-French Three-Factor Model∗

Characterizing the instantaneous investment opportunity set by the real interest rate and the maximum Sharpe ratio, a simple model of time varying investment opportunities is posited in which these two variables follow correlated Ornstein-Uhlenbeck processes, and the implications for stock and bond valuation are developed. The model suggests that the prices of certain portfolios that are relate...

Drug development costs when financial risk is measured using the Fama-French three-factor model.

In a widely cited article, DiMasi, Hansen, and Grabowski (2003) estimate the average pre-tax cost of bringing a new molecular entity to market. Their base case estimate, excluding post-marketing studies, was $802 million (in $US 2000). Strikingly, almost half of this cost (or $399 million) is the cost of capital (COC) used to fund clinical development expenses to the point of FDA marketing appr...